CN102119173B - 凝溶胶蛋白结合剂组合物及其用途 - Google Patents

凝溶胶蛋白结合剂组合物及其用途 Download PDF

Info

Publication number
CN102119173B
CN102119173B CN200780101031.4A CN200780101031A CN102119173B CN 102119173 B CN102119173 B CN 102119173B CN 200780101031 A CN200780101031 A CN 200780101031A CN 102119173 B CN102119173 B CN 102119173B
Authority
CN
China
Prior art keywords
gelsolin
antibody
polypeptide
binding
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780101031.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102119173A (zh
Inventor
沈恩允
余征
周敏
郭菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Cotimes Biotech Co Ltd
Original Assignee
Beijing Cotimes Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Cotimes Biotech Co Ltd filed Critical Beijing Cotimes Biotech Co Ltd
Publication of CN102119173A publication Critical patent/CN102119173A/zh
Application granted granted Critical
Publication of CN102119173B publication Critical patent/CN102119173B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200780101031.4A 2007-08-15 2007-08-15 凝溶胶蛋白结合剂组合物及其用途 Expired - Fee Related CN102119173B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/002467 WO2009021360A1 (en) 2007-08-15 2007-08-15 Gelsolin binding agent compositions and uses of same

Publications (2)

Publication Number Publication Date
CN102119173A CN102119173A (zh) 2011-07-06
CN102119173B true CN102119173B (zh) 2015-04-08

Family

ID=40350342

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780101031.4A Expired - Fee Related CN102119173B (zh) 2007-08-15 2007-08-15 凝溶胶蛋白结合剂组合物及其用途
CN200880110871.1A Expired - Fee Related CN101855236B (zh) 2007-08-15 2008-08-15 尿凝溶胶蛋白的检测和定量

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880110871.1A Expired - Fee Related CN101855236B (zh) 2007-08-15 2008-08-15 尿凝溶胶蛋白的检测和定量

Country Status (5)

Country Link
US (2) US8367356B2 (enExample)
EP (2) EP2188309A4 (enExample)
JP (2) JP2010537625A (enExample)
CN (2) CN102119173B (enExample)
WO (2) WO2009021360A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024087613A1 (zh) 2022-10-24 2024-05-02 浙江宇龙药业有限公司 一种含七氟异丙基的双酰胺类化合物及其中间体化合物，其制备方法与用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535718B1 (en) 2007-05-11 2014-07-09 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
US8367356B2 (en) * 2007-08-15 2013-02-05 Beijing Cotimes Biotech Co., Ltd. Gelsolin binding agent compositions and uses of same
US20100136610A1 (en) * 2008-12-03 2010-06-03 Jeong-Yeol Yoon Methods And Microfluidic Devices For Single Cell Detection Of Escherichia Coli
US9678005B1 (en) 2008-12-03 2017-06-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Devices and methods for detection of microorganisms
US9562855B1 (en) 2009-12-03 2017-02-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Devices and methods for detection of microorganisms via MIE scattering
EP2725360A1 (en) * 2012-10-24 2014-04-30 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Biomarkers for the prognosis of ischemic stroke
WO2016054383A1 (en) * 2014-10-01 2016-04-07 Henry Ford Health System Methods for treating sepsis and biomarkers related thereto
FR3036188B1 (fr) * 2015-05-12 2019-06-07 Biomerieux Prediction du risque de developper, pour des patients admis en service de reanimation, une infection disseminee
CN108020663A (zh) * 2016-11-02 2018-05-11 张曼 尿液凝溶胶蛋白及其多肽片段在肺腺癌中的应用
US10905585B1 (en) 2020-02-21 2021-02-02 Robert Sabin Respiratory therapeutic electric heat source face mask
EP4146244B1 (en) * 2020-05-04 2025-11-26 BioAegis Therapeutics Inc. Compositions comprising gelsolin for treating frailty
US20230357388A1 (en) * 2020-09-25 2023-11-09 The Francis Crick Institute Limited Immunotherapy
CN115308010B (zh) * 2021-05-06 2025-05-23 威高集团有限公司 一种抗体保护剂和采血管

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650487A (en) 1988-09-09 1997-07-22 The Regents Of The University Of California Serum immunoregulatory polypeptides and uses therefor
WO1994003601A2 (en) 1992-08-03 1994-02-17 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2008500952A (ja) 2003-07-15 2008-01-17 ジェノバ・リミテッド 心臓血管障害で減少する分泌ポリペプチド種
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
CN1746676A (zh) * 2004-09-08 2006-03-15 中国医学科学院肿瘤医院肿瘤研究所 一种胰腺癌血清标志分子的检测方法
WO2006091861A2 (en) 2005-02-25 2006-08-31 Ppd Biomarker Discovery Sciences, Llc Compositions and methods relating to cns lymphoma
WO2007109056A2 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
WO2007137582A1 (en) 2006-05-30 2007-12-06 Antibodyshop A/S Methods and devices for rapid assessment of severity of injury and disease
US8367356B2 (en) * 2007-08-15 2013-02-05 Beijing Cotimes Biotech Co., Ltd. Gelsolin binding agent compositions and uses of same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Identification of two sites in gelsolin with different sensitivities to adenine nucleotides;LAHAM L.E等;《Eur.J.Biochem》;20050907;第234卷;第1-7页 *
Immuno-identification of Ca2+-induced Conformational Changes in Human Gelsolin and Brevin;Hwo S等;《THE JOURNAL OF CELL BIOLOGY》;19860101;第102卷(第1期);第227-238页 *
The Role of F-Actin Cytoskeleton-Associated Gelsolin in the Guinea Pig Capacitation and Acrosome Reaction;Cabello-Agueros等;《Cell Motility and the Cytoskeleton》;20031031;第56卷(第2期);第94-108页 *
Topological assignment of the N-terminal extension of plasma gelsolin to the gelsolin surface;FOCK U等;《BIOCHEMICAL JOURNAL》;20050101;第385卷(第3期);第660页右栏第3-4段，第661页图1，第662图5、第663页图6 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024087613A1 (zh) 2022-10-24 2024-05-02 浙江宇龙药业有限公司 一种含七氟异丙基的双酰胺类化合物及其中间体化合物，其制备方法与用途

Also Published As

Publication number Publication date
EP2188304A1 (en) 2010-05-26
WO2009021360A1 (en) 2009-02-19
US20110207152A1 (en) 2011-08-25
EP2188309A1 (en) 2010-05-26
WO2009024070A1 (en) 2009-02-26
JP2010537625A (ja) 2010-12-09
CN101855236B (zh) 2015-03-04
CN101855236A (zh) 2010-10-06
EP2188309A4 (en) 2011-03-30
US8367356B2 (en) 2013-02-05
US20120156700A1 (en) 2012-06-21
JP2010536043A (ja) 2010-11-25
EP2188304A4 (en) 2011-07-06
CN102119173A (zh) 2011-07-06

Similar Documents

Publication Publication Date Title
CN102119173B (zh) 凝溶胶蛋白结合剂组合物及其用途
US20220251230A1 (en) Monoclonal antibodies and methods of use
JP7328658B2 (ja) 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用
KR20210129259A (ko) 항-cd47 항체 및 그 용도
US20220259307A1 (en) Cd33 antibodies and methods of using the same to treat cancer
KR20140053974A (ko) 항-알파 시누클레인 결합 분자
KR101830181B1 (ko) 인간화 il-25 항체
CN114341182A (zh) Dll3靶向抗体及其用途
EP3953385A1 (en) Cd19 antibodies and methods of using the same
US20110158997A1 (en) Single chain fragment variable antibody libraries and uses thereof
JP2024530166A (ja) Ｃｄ３標的化抗体及びそれらの使用
KR20180012279A (ko) 신경 질환의 치료를 위한 방법
US20210047436A1 (en) Anti- polysialic acid antibodies and uses thereof
AU2007213655A1 (en) Antibodies against secreted fri zzled related protein-4 (SFRP-4 )
KR20130132904A (ko) 인간 모노클로날 항체
WO2024031009A2 (en) Anti-cd24 antibodies and uses thereof
JP2024531913A (ja) 抗ｈｅｒ２抗体及びそれらの使用
MX2008010145A (en) Antibodies against secreted fri zzled related protein-4 (sfrp-4 )

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150408